

PROGENICS PHARMACEUTICALS INC  
Form 8-K  
December 01, 2005

---

---

**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) December 1, 2005

**Progenics Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other  
jurisdiction  
of incorporation)

**000-23143**  
(Commission  
File Number)

**13-3379479**  
(IRS Employer  
Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York  
(Address of principal executive offices)

10591  
(Zip Code)

Registrant's telephone number, including area code (914) 789-2800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-



**Item 7.01. Regulation FD Disclosure**

Progenics Pharmaceuticals, Inc. announced that it is today initiating a phase 1b clinical trial of a new investigational HIV therapy - a humanized monoclonal antibody that specifically binds CCR5, a receptor that serves as a portal of entry for HIV into cells of the immune system. PRO 140 belongs to a new class of drugs, viral-entry inhibitors, which are designed to prevent HIV from entering and infecting healthy cells. The phase 1b trial is designed to evaluate the tolerability, pharmacology and antiviral activity of PRO 140 in patients infected with HIV (human immunodeficiency virus), the virus that causes AIDS. A copy of the press release is attached hereto as Exhibit 99.1 and the information contained therein is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

The information furnished pursuant to Item 7.01 in this Form 8-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Securities Act of 1933 or the Securities Exchange Act of 1934. We undertake no duty or obligation to publicly update or revise the information furnished pursuant to Item 7.01 in this Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits

**Exhibit No.    Description**

99.1    Press Release dated December 1, 2005 regarding PRO 140 Phase 1b trial

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROGENICS PHARMACEUTICALS, INC.

By: /s/ ROBERT A. MCKINNEY

Robert A. McKinney  
Chief Financial Officer, Vice President,  
Finance and Operations and Treasurer

Date: December 1, 2005